CD82 and prostate carcinoma: A present study suggests that KAI1/CD82 functions in suppressing TGF‐β1‐ and Wnt‐induced EMT in prostate cancer cells by inhibiting the TGF‐β1/Smad and Wnt/β-catenin pathways, resulting in the development of a motile and invasive mesenchymal phenotype related to the initiation of the metastatic cascade [11].